| Metric | Q2 FY27 | Q1 FY27 | Q2 FY26 |
|---|---|---|---|
| Revenue from operations | 1122.3 | 1063.1 | 804.2 |
| Other income | 15.0 | 29.0 | 19.7 |
| Total income | 1137.3 | 1092.1 | 823.9 |
| Profit before exceptional items & tax | 147.4 | 152.7 | 133.1 |
| Profit before tax | 147.4 | 152.7 | 133.1 |
| Net profit | 112.3 | 116.2 | 102.1 |
| Operating margin | 13.0% | 14.0% | 16.2% |
A dash means the filing did not report that period; n/m means not meaningful (margin on near-zero revenue). Growth is not shown when either period was a loss. Operating profit excludes other income.
| Net profit, year on year | +10.00% |
|---|---|
| Net profit, quarter on quarter | -3.40% |
| Revenue, year on year | +39.60% |
| Operating profit, year on year | +16.80% |
| Operating profit, quarter on quarter | +7.00% |
BSE results filing, NSE: INDGN. Figures extracted from the filing.
Indegene Ltd: key numbers
- Share price
- ₹594.70
- Market cap
- ₹14,328 Cr
- Revenue (annual)
- ₹3,510 Cr
- Net profit (annual)
- ₹401.1 Cr
- P/E (TTM)
- 35.7×Sector 52.0×
- Promoter holding
- 0.00%+0.00% QoQ
- FII holding
- 12.40%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Indegene Ltd
All →Indegene Management Change
Indegene's Company Secretary and Compliance Officer Srishti Ramesh Kaushik resigned, effective 02-Dec-2026. The resignation cites future career advancement.
Indegene Employee Stock Options
Indegene Limited allotted 52,194 equity shares under its ESOP schemes, raising paid-up capital to Rs.48.21 Crore. No cash fund raise is involved, so no event value applies.
Indegene Investor Presentation: Key Takeaways
Q2 FY27 revenue INR 11,223M (+39.5% YoY, +5.6% QoQ), EBITDA margin 16.7%, PAT INR 1,123M (+10% YoY). BioPharm integration ahead of plan.
Indegene Results Update
Indegene reported Q2 FY27 revenue of ₹11,223M, up 39.5% YoY, with PAT of ₹1,123M. H1 USD revenue growth reached a four-year high of 27.0%.
Indegene Merger & Restructuring
Indegene Ltd disclosed that its step-down wholly owned subsidiary, Indegene Portugal Unipessoal LDA, was incorporated on 23 October 2026. The entity has nil turnover and is yet to begin operations.
Indegene Business Update
Indegene received Frost & Sullivan's 2026 Global Enabling Technology Leadership award for AI-powered pharma commercialization. The recognition highlights its domain-led AI platform and workflow transformation capabilities.